Patients' lung tumors are matched with targeted drugs

04/18/2010 | Reuters

Researchers said they were able to delay tumor growth in patients with advanced lung cancer after treatment with drugs that target specific cancer biomarkers. Among the drugs tested, Nexavar, which is designed to target the KRAS gene mutation, was found to yield the best results. Nexavar, or sorafenib, has the "potential to blaze a trail in lung cancer as well," one of the researchers said.

View Full Article in:


Published in Brief: